In silico identification of vaccine targets for 2019-nCoV [version 1; peer review: 2 approved]

Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus prot...

Full description

Saved in:
Bibliographic Details
Published inF1000 research Vol. 9; p. 145
Main Authors Hyun-Jung Lee, Chloe, Koohy, Hashem
Format Journal Article
LanguageEnglish
Published F1000 Research Ltd 2020
Subjects
Online AccessGet full text
ISSN2046-1402
2046-1402
DOI10.12688/f1000research.22507.1

Cover

Abstract Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
AbstractList Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Author Koohy, Hashem
Hyun-Jung Lee, Chloe
Author_xml – sequence: 1
  givenname: Chloe
  surname: Hyun-Jung Lee
  fullname: Hyun-Jung Lee, Chloe
  organization: MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, UK, Oxford, UK
– sequence: 2
  givenname: Hashem
  orcidid: 0000-0002-3640-7043
  surname: Koohy
  fullname: Koohy, Hashem
  email: hashem.koohy@rdm.ox.ac.uk
  organization: MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, UK, Oxford, UK
BookMark eNqFkctuFDEQRS0UJELILyAv2fRQtrvddmCDRjxGipQNsEFgVdvl4KjTHuyeQfl75kEQsMnKJeucq7LvU3Yy5YkYey5gIaQ25mUUAFCoEhb_fSFlB_1CPGKnElrdiBbkyV_zE3Ze681OAGuVlv0p-7aaeE1j8pmnQNOcYvI4pzzxHPkWvU8T8RnLNc2Vx1y4BGGbaZk_8y9bKnVPild8TVR4oW2inxdcclyvS95S-PqMPY44Vjr_fZ6xT-_eflx-aC6v3q-Wby4br7QRDYkY22hNK4AIh6AGMsoE1EMcjOxURxFDUH3XxzZ0Jki0viVSolfCaxjUGVsdc0PGG7cu6RbLncuY3OEil2uHZU5-JCfJemm1tySG1gIOQkhJfSvBAmhDu6wXx6zdG35sqM7uNlVP44gT5U11UhkD0IEUO_T1EfUl11ooOp_mw_fNBdPoBLhDS-6fltyhJbfX9X_6_eYPihdHMaLfjPPdHnJ_qAfkX0GerQo
CitedBy_id crossref_primary_10_1111_imr_12897
crossref_primary_10_3389_fimmu_2022_931155
crossref_primary_10_1038_s41598_021_86986_6
crossref_primary_10_1155_2021_6693909
crossref_primary_10_1111_tan_13956
crossref_primary_10_22354_in_v24i3_898
crossref_primary_10_1096_fj_202001115R
crossref_primary_10_1186_s12967_025_06285_w
crossref_primary_10_1016_j_addr_2021_01_007
crossref_primary_10_1038_s41467_023_42430_z
Cites_doi 10.1093/nar/gky1006
10.1186/s13073-018-0577-7
10.4049/jimmunol.1700893
10.1101/2020.02.03.933226
10.3389/fimmu.2019.02501
10.1016/S2542-5196(20)30035-8
ContentType Journal Article
Copyright Copyright: © 2020 Hyun-Jung Lee C and Koohy H
Copyright: © 2020 Hyun-Jung Lee C and Koohy H.
Copyright_xml – notice: Copyright: © 2020 Hyun-Jung Lee C and Koohy H
– notice: Copyright: © 2020 Hyun-Jung Lee C and Koohy H.
DBID C-E
CH4
AAYXX
CITATION
7X8
DOA
DOI 10.12688/f1000research.22507.1
DatabaseName F1000Research
Faculty of 1000
CrossRef
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Women's Studies
EISSN 2046-1402
ExternalDocumentID oai_doaj_org_article_2e9c296c9e1b490ab1122e742090068e
10_12688_f1000research_22507_1
GrantInformation_xml – fundername: Medical Research Council
GroupedDBID 3V.
53G
5VS
7X7
88I
8FE
8FH
8FI
8FJ
ABUWG
ACGOD
ACPRK
ADACO
ADBBV
ADRAZ
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAWUL
BBAFP
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C-E
CH4
DIK
DWQXO
FRP
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HYE
KQ8
LK8
M2P
M7P
OK1
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
PROAC
RPM
AAFWJ
AAYXX
AFPKN
ALIPV
AOIJS
CCPQU
CITATION
HMCUK
M48
M~E
PGMZT
PHGZM
PHGZT
UKHRP
W2D
7X8
PQGLB
PUEGO
ID FETCH-LOGICAL-c3681-e1ff4f98410eeabd3be838da6bfb82535efadd3757f4d58d2a9c4ee31731c60b3
IEDL.DBID M48
ISSN 2046-1402
IngestDate Wed Aug 27 01:31:59 EDT 2025
Thu Sep 04 18:06:57 EDT 2025
Tue Jul 01 04:27:10 EDT 2025
Thu Apr 24 23:04:08 EDT 2025
Mon Jan 18 12:18:45 EST 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords T cell cross-reactivity
Coronavirus
vaccine development
adaptive immunity
immunogenicity
Language English
License http://creativecommons.org/licenses/by/4.0/: This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3681-e1ff4f98410eeabd3be838da6bfb82535efadd3757f4d58d2a9c4ee31731c60b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3640-7043
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.12688/f1000research.22507.1
PQID 2388005021
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_2e9c296c9e1b490ab1122e742090068e
proquest_miscellaneous_2388005021
crossref_citationtrail_10_12688_f1000research_22507_1
crossref_primary_10_12688_f1000research_22507_1
faculty1000_research_10_12688_f1000research_22507_1
ProviderPackageCode C-E
CH4
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-00-00
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 2020-00-00
PublicationDecade 2020
PublicationTitle F1000 research
PublicationYear 2020
Publisher F1000 Research Ltd
Publisher_xml – name: F1000 Research Ltd
References V Jurtz (ref-6) 2017; 199
C Lee (ref-9) 2020
A Karapetyan (ref-7) 2019; 10
S Ahmed (ref-8) 2020
M Pogorelyy (ref-5) 2018; 10
(ref-1) 2020
R Kock (ref-2) 2020
C Lee (ref-4) 2020
R Vita (ref-3) 2019; 47
References_xml – volume: 47
  start-page: D339-D343
  year: 2019
  ident: ref-3
  article-title: The Immune Epitope Database (IEDB): 2018 update.
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gky1006
– year: 2020
  ident: ref-4
  article-title: In silico identification of vaccine targets for 2019-nCoV (Custom code).
  publication-title: Zenodo.
– volume: 10
  year: 2018
  ident: ref-5
  article-title: Exploring the pre-immune landscape of antigen-specific T cells.
  publication-title: Genome Med.
  doi: 10.1186/s13073-018-0577-7
– volume: 199
  start-page: 3360-3368
  year: 2017
  ident: ref-6
  article-title: NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.1700893
– year: 2020
  ident: ref-8
  article-title: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
  doi: 10.1101/2020.02.03.933226
– year: 2020
  ident: ref-1
  article-title: 2019-NCoV Outbreak Is an Emergency of International Concern.
– volume: 10
  year: 2019
  ident: ref-7
  article-title: TCR Fingerprinting and Off-Target Peptide Identification.
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2019.02501
– year: 2020
  ident: ref-2
  article-title: 2019-nCoV in context: lessons learned?
  publication-title: Lancet Planet Health.
  doi: 10.1016/S2542-5196(20)30035-8
– year: 2020
  ident: ref-9
  article-title: In silico identification of vaccine targets for 2019-nCoV (Data tables).
  publication-title: Zenodo.
SSID ssj0000993627
Score 2.326448
Snippet Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it...
Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it...
SourceID doaj
proquest
crossref
faculty1000
SourceType Open Website
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 145
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NSx0xEA_ioehBWm3p64ekUOhp6-ZzN-2pFcUW9FSLUNqQZCdokX3i0wf97zuTXR9PPLyLt2XZkJCZnZlfMvMbxt53DuhyDrEJupdKK62rYFOqhLBZmoSAo_SMPD6xR6f6-5k5W2r1RTlhAz3wsHF7ElySziYHImpXh4gBggQEdLWj8gYg64uPS2Dq7xD3oGWmWmmJALASJY2nlAdLi5Av06n2yKZz_hFVmo5Z7nmmQuC_yTZzIAaMf_T9A2tdXNDhU7Y1xo78y7DmZ2wN-m325Hi8Hd9mW6Ud5YcZH5MDd9ifbz2fXVyitPlFN-YFFVHwaebzkGgcH5LBZxzDV46O2lX9_vQn_zUfTtK4-MyvAK75UOTyiUteeMjn0P1-zk4PD37sH1VjR4UqKduKCkTOOrtWixogxE5FaFXbBRtzRKioDGS0d6oxTdadaTsZXNIAGGMokWwd1Qu23k97eMl4E7WRuUk5maCTCG1SumlBgdIpRgsTZu5206eRbpy6Xlx6gh0kBX9PCr5IwYsJ21uMuxoIN1aO-ErCWnxNhNnlBaqRH9XIr1KjCVNLovaLOVZN_e5OJTz-lnTXEnqY3s68JJKd2mAE9eoxlveabUgC-uXs5w1bv7m-hbcYDd3E3aL4_wGRnQB0
  priority: 102
  providerName: Directory of Open Access Journals
Title In silico identification of vaccine targets for 2019-nCoV [version 1; peer review: 2 approved]
URI http://dx.doi.org/10.12688/f1000research.22507.1
https://www.proquest.com/docview/2388005021
https://doaj.org/article/2e9c296c9e1b490ab1122e742090068e
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxQxEB_6AWIfilbF-rFEEHzauvna3TyI2NJahRYRT-4tJNmkVo5dvW3F_vdOcrnDolhf9mFJNsvMJPObj8wAPO-Uj8E5tE1QvZSCC1Ga2rmS0jow6dDgSD0jT07r44l4P5XTNVi2S80EHP9q2sV-UpP5bO_n96vXuOFfpdoINVpwITqpc3GcL3soodFrsg6bKWYU0_ky5P-6QER4Zsdb1AxNw5KmBJ_i35-6prNSaf8t2Aom1sa4iuP_OMeTcjq6A9sZVZI3CzG4C2u-34FbJzluvgPbqVHli5HktMF7oN71ZDyfoRyQ8y5nDCUmkSGQH8bFeWSRJj4SBLYEVbgq-4Ph832YHB1-OjgucxuF0vG6paWnIYigWkEr743tuPUtbztT22DRPuTSBzzkeCObIDrZdswoJ7xHYMGpqyvLH8BGP_T-IZDGCslC44KTRjhqWsdF03ruuXDW1n4X5JJQ2uUa47HVxUxHWyMSWF8jsE4E1nQXXq7mfVtU2bhxxn7kw2p0rJKdXgzzM503nWZeOaZqpzy1QlXGIrhkvhGsUvFqDP4u_42LerXGTUs_W3Jb416MARbT--Fy1CxW1qkkwqZH_zHmMdxm0XhP_pwnsHExv_RPEeFc2ALWm2lTwOb-4emHj0XyE-Dz7ZQWSZh_Aeyn9-E
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+silico+identification+of+vaccine+targets+for+2019-nCoV&rft.jtitle=F1000+research&rft.au=Hyun-Jung+Lee%2C+Chloe&rft.au=Koohy%2C+Hashem&rft.date=2020&rft.issn=2046-1402&rft.eissn=2046-1402&rft.volume=9&rft.spage=145&rft_id=info:doi/10.12688%2Ff1000research.22507.1&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2046-1402&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2046-1402&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2046-1402&client=summon